The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

US regulators approved Moderna Inc.’s vaccine to prevent a common respiratory illness for more adults, a potential easing of the Trump administration’s opposition to mRNA technology.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. The CDC estimates 15,000–20,000 annual RSV-associated hospitalizations in the U.S ...

The committee’s recommendation was worded in such a way as to include any RSV with a license for use in this age group, so should, in theory, apply as well to the Moderna vaccine now that the ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

FDA Approves Moderna's RSV Vaccine, MRESVIA, For Younger Adults June 12, 2025 — 09:05 pm EDT Written by RTTNews.com for RTTNews -> ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection. ... FDA approves expanded use of Moderna’s RSV shot, ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.